Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
128 participants
INTERVENTIONAL
2026-02-28
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators aim to determine whether blocking the acute subjective effects (via risperidone) will influence the acute or protracted effects of psilocybin as measured via self-report, biochemical, or psychophysiological measures. The study also aims to determine if individual variability in stress reactivity or regulation predicts acute (day of dosing) or protracted (1-week later) effects of psilocybin.
A single site will recruit 128 participants aged 18 to 65 who do not meet criteria for any psychiatric diagnoses. A series of questionnaires, blood labs, and medical exams including electrocardiogram will determine inclusion into the study. Once accepted into the study, participants will complete baseline measures assessing cortisol and brain-derived neurotrophic factor (BDNF) levels, cognitive flexibility, mood, well-being, personality traits, and anxiety levels.
Participants will then be randomly assigned into one of the following groups:
i) high dose psilocybin (25mg; "active dose") in combination with placebo pretreatment ii) high dose psilocybin (25mg; "active dose") in combination with risperidone pretreatment (1mg) iii) low dose psilocybin (1mg "active control") in combination with placebo pretreatment, iv) low dose psilocybin (1mg "active control") in combination with risperidone pretreatment (1mg).
Outcome measures will be assessed at 1-week and 1-month after each dosing session.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-dose psilocybin + placebo
placebo + 25 mg psilocybin (+60 min)
Psilocybin 25 mg
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
Placebo
inactive placebo
Low-dose psilocybin + placebo
placebo + 1 mg psilocybin (+60 min)
Psilocybin 1 mg
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
Placebo
inactive placebo
High-dose psilocybin + risperidone
1 mg risperidone + 25 mg psilocybin (+60 min)
Psilocybin 25 mg
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
Risperidone 1 MG
risperidone 1mg capsules
Low-dose psilocybin + risperidone
1 mg risperidone + 1 mg psilocybin (+60 min)
Psilocybin 1 mg
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
Risperidone 1 MG
risperidone 1mg capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Psilocybin 25 mg
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
Psilocybin 1 mg
The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
Risperidone 1 MG
risperidone 1mg capsules
Placebo
inactive placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages 18 to 65 years of age at the time of screening
* Ability to read/write in English
* Agree not to consume psychoactive drugs 24 hours before dosing sessions or consume psychedelics during duration of study participation
* At least one self-reported positive experience prior to study participation with a psychoactive substance, specifically those known for altering perception or inducing hallucinatory effects (cannabis or psychedelics, including psilocybin, LSD, DMT, mescaline) or experience with non-pharmacological altered states of consciousness (meditation, breathwork)
Exclusion Criteria
* Serious electrocardiogram abnormality, i.e., evidence of ischemia, myocardial infarction, QTc (Fridericia formula) prolongation (QTc \> 0.45 for men, QTc \> 0.47 for women).
* Abnormal liver enzymes (AST, ALT, GGT ≥4 times upper normal limit)
* Pre-existing low white blood cell count or a history of drug-induced leukopenia/neutropenia
* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
* History of epilepsy or seizures, neuroleptic malignant syndrome or tardive dyskinesia
* Hypertension (\>140mmHg systolic or 90mmHg) or Tachycardia (HR \>100bpm) as measures by best result of maximum of three vital sign recordings in a supine position after a 5 min resting period. Participants with a blood pressure not higher than 165/95 or a heart rate of not higher than 110bpm can be conditionally enrolled but dosing will only happen if the vitals at the dosing sessions are in the limits outlined above for inclusion.
* Current psychiatric diagnoses, such as major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, moderate to severe substance use disorders, eating disorders, personality disorders, post-traumatic stress disorder
* Lifetime or current psychiatric diagnoses of psychosis, schizophrenia, bipolar disorder
* Family history: a first- or second degree relative with a history of schizophrenia or other psychotic disorders, bipolar I or II
* Medication: Any medication with the potential to interact with the investigational medicinal products, especially those with serotonergic mechanisms of actions like SSRIs, SNRIs or MAO-Inhibitors as well as other antipsychotics. Medication with potential drug-drug interactions (especially uridine 5'-diphospho-glucuronosyltransferase (UGT) and ALDH inhibitors and alcohol dehydrogenase (ADH) inhibitors for psilocybin and CYP2D6- and to a lesser extend CYP3A4 modulators for risperidone) are prohibited for at least 5 half-lives of the active moiety before the dosing.
* Serotonergic psychedelic use in the past 3 months (e.g. psilocybin, LSD, DMT, mescaline)
* Serious adverse events following previous psychedelic use
* Currently pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study
* Acceptable methods of contraception include oral contraceptives, barrier with spermicide, IUD, medroxyprogesterone acetate (Depo Provera), contraceptive patch, vaginal contraceptive ring, or being post-menopausal or deemed medically unable to become pregnant (i.e., due to hysterectomy)
* Current or recent (within 12 weeks) participation in a clinical trial involving medication administration
* Any sensitivity or adverse reaction to previous use of a hallucinogen or risperidone
* Cognitive impairment (Folsetin Mini Mental State Exam score \< 24)
* A disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).
* Suffered a traumatic brain injury with one of the following symptoms
* Loss of consciousness \>30min
* Alteration of consciousness/mental state \>24h
* Post-traumatic amnesia \>1 day
* Glasgow Coma Scale (best available score in first 24 hours) \<13
* The participant experienced a significant life event (such as pending loss of housing, family status change, loss of a close friend or relative) that could affect stability in the past 30 days.
* Any other circumstances that, in the opinion of the investigators, compromises participant safety
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Leah Mayo, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB24-1121
Identifier Type: -
Identifier Source: org_study_id